about
Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosisTrovafloxacin is active against Toxoplasma gondiiA mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase IIImportance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action.Anti-tubercular drug designing by structure based screening of combinatorial libraries.Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis.Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICsInteractions of CcdB with DNA gyrase. Inactivation of Gyra, poisoning of the gyrase-DNA complex, and the antidote action of CcdA.Ciprofloxacin resistance in Campylobacter jejuni isolates: detection of gyrA resistance mutations by mismatch amplification mutation assay PCR and DNA sequence analysisDNA gyrase-mediated natural resistance to fluoroquinolones in Ehrlichia spp.Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy.Salmonella typhimurium gyrA mutations associated with fluoroquinolone resistance.Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutationsEffect of magnesium complexation by fluoroquinolones on their antibacterial properties.Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex.Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential.A pyrimido[1,6-a]benzimidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cytotoxic potentialConversion of DNA gyrase into a conventional type II topoisomeraseMolecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions.DNA gyrase can cleave short DNA fragments in the presence of quinolone drugs.Replicative helicases can translocate through abasic site-induced covalent topoisomerase IV-DNA complexes.In vitro activities of antibiotics against Plasmodium falciparum are inhibited by iron.Probing the role of the ATP-operated clamp in the strand-passage reaction of DNA gyrase.Mode of action of GR122222X, a novel inhibitor of bacterial DNA gyrase.Adaptive mutations produce resistance to ciprofloxacin.Bacteriophage PSP3 and phi R73 activator proteins: analysis of promoter specificities.A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complexNew quinolones and gram-positive bacteria.Evidence for a conformational change in the DNA gyrase-DNA complex from hydroxyl radical footprinting.The alpha4 residues of human DNA topoisomerase IIalpha function in enzymatic activity and anticancer drug sensitivity.Interaction between ciprofloxacin and chloroquine in mice infected with chloroquine resistant Plasmodium berghei: interaction between ciprofloxacin and chloroqune.Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in Quinolone-resistant Shigella dysenteriae serotype 1 clinical isolates from Kolkata, India.Analysis of ciprofloxacin-resistant Salmonella strains from swine, chicken, and their carcasses in Taiwan and detection of parC resistance mutations by a mismatch amplification mutation assay PCR.Topoisomerase IV catalysis and the mechanism of quinolone action.Mechanism of quinolone action. A drug-induced structural perturbation of the DNA precedes strand cleavage by topoisomerase IV.A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine.The interaction of Escherichia coli topoisomerase IV with DNA.Analysis of the NH2-terminal 87th amino acid of Escherichia coli GyrA in quinolone-resistance.Biological degradation and microbial function effect of norfloxacin in a soil under different conditions
P2860
Q28378877-503499FC-9DFF-4577-A6C7-5F246227B32EQ28379193-8E44A2FE-8999-42BA-AFBD-68CFCF2FCA5AQ30448695-158E0055-0CFA-4403-AFD3-E05C574B27ADQ30453068-52059D82-0C31-41F6-A465-B906DCCC5D23Q33720784-38157C53-9944-402E-9EA1-1306A35B9000Q33758823-EE84267D-294D-4C52-B462-1901EDB9F7B1Q33762110-D10D678D-2BE8-433E-A997-8F5E116B2A74Q33858140-A1E26C17-FB3F-4185-96AE-0CE9F5B5B65EQ33963001-8375350F-3FBB-477F-9E0B-4AD9D9D9F834Q33982545-D16D6080-E949-4D19-AD35-6B5899B9F353Q34314426-EDF96C15-94D8-45C9-98E2-4D8709274BA9Q35116590-B4C015FA-1E5E-41F0-97BE-7784F5A68A6EQ35810189-0CFE68C8-0A15-4ED4-9A32-666879BCAA35Q35823176-CEFADFFA-75F6-4F4F-930E-F050F91F7A33Q35890421-A11AE659-1C1A-4360-9C97-AE8E6F79B568Q35897465-4BF5203B-05BB-49E8-A7AE-0CAA3CD0BA8BQ35904133-335ECBC2-90E5-4466-8380-37AA9E28B417Q37039334-24CB8BE0-E5FF-4C51-A63E-75CE55E9E825Q38320285-9DB1FDA3-E52C-4278-9722-C7665B0931AEQ38344294-5510F151-58C5-4D77-A0FF-6382A0F0F38FQ38668700-851E6112-D8CF-4488-85A0-C3F396E9778AQ39477444-10FFE300-9844-4696-B814-9BBD3ABCECC8Q39718513-724CB9FC-076F-4C5B-9223-97A60329B94FQ39781473-C58E718E-8591-4063-A915-4135622A4351Q39784978-F8A1865E-B991-46D6-B8A9-6E2D9E329FC7Q39842845-870849FE-F0D5-47CE-8D44-304CA5B315B2Q39864841-ED27CCD2-0EF1-444F-B66E-784E0914DAD9Q40284884-3C7926D8-8F65-44EC-99C5-4F426A33938BQ40399549-B6BB5A4F-D249-4C29-95DE-004D0A12ACDAQ40773283-22E09841-DA62-45A7-A06C-5B7B67F4CCF3Q41932012-54A55FB3-D09F-4363-AAA8-416A5FE680DBQ42708801-4AFAECBC-B657-4933-9A17-6FFCFC77A868Q46127340-AF8D5735-6CF6-413D-9970-DFDD080C2C52Q47891380-DF8BF7D9-F80C-4847-8526-6E38D316B443Q53970744-55D0C8D9-152E-403A-A96E-C5DA1AF04C1FQ54182306-E2A8F227-77FF-4680-904D-0C16C1F44A2DQ54601468-DB41F8DF-00E2-4F77-A51D-70D944094432Q54619902-F1D5B8B2-06D2-4E34-AF18-9F29F26315B9Q57734611-CA24F333-4E9F-48F5-9F17-2CB1AA68B4B4
P2860
description
1992 nî lūn-bûn
@nan
1992 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
The molecular basis of quinolone action.
@ast
The molecular basis of quinolone action.
@en
type
label
The molecular basis of quinolone action.
@ast
The molecular basis of quinolone action.
@en
prefLabel
The molecular basis of quinolone action.
@ast
The molecular basis of quinolone action.
@en
P356
P1476
The molecular basis of quinolone action.
@en
P2093
P304
P356
10.1093/JAC/30.4.409
P407
P577
1992-10-01T00:00:00Z